Key result
Wild-type TNNT2 overexpression restores contractile function and calcium handling in TNNT2-R151W mutated iPSC-derived cardiomyocytes.
Why the study?
DCM is the most prevalent pediatric cardiomyopathy with poor prognosis, and severe donor shortages for heart transplantation highlight an urgent need for alternative therapies.
Does overexpression of wild-type TNNT2 rescue cellular and contractile dysfunction in iPSC-derived cardiomyocytes from children with TNNT2-R151W mutated dilated cardiomyopathy?
Does overexpression of wild-type TNNT2 rescue cellular and contractile dysfunction in iPSC-derived cardiomyocytes from children with TNNT2-R151W mutated dilated cardiomyopathy?
Overexpression of wild-type TNNT2 rescues sarcomere insufficiency and Ca2+ handling disturbances in iPSC-derived cardiomyocytes from patients with TNNT2-R151W pediatric dilated cardiomyopathy, suggesting potential for gene replacement therapy.
Answers are grounded in this paper and cite their sources.
Supports gene replacement exploration in TNNT2-mutated pediatric DCM; hypothesis-generating pending in vivo validation.
Dilated cardiomyopathy (DCM) is the most prevalent pediatric cardiomyopathy and has a poor prognosis. Although heart transplantation is the only curative option, the severe donor shortage in Japan underscores an urgent need for alternative therapies. Here, we generated induced pluripotent stem cell (iPSC) lines from two unrelated children with the same TNNT2‐R151W mutation. We then investigated the cellular characteristics of the cardiomyocytes derived from these iPSC lines (R151W iPSC‐CMs) and evaluated their contractile function in pillar‐based engineered heart tissue (EHT). We also assessed the therapeutic potential of overexpressing wild‐type TNNT2 in patient‐derived iPSCs (wtTNNT2‐OE‐iPSCs). R151W‐iPSC‐CMs exhibited pronounced sarcomere disarray, attenuated Ca 2+ transient amplitude, prolonged time to peak, and delayed decay tau. These characteristics are indicative of failing myocardium and were restored in wtTNNT2‐OE‐iPSC‐CMs. Pillar‐based EHT assays revealed a substantial decrease in contractile force in R151W‐EHTs compared to wtTNNT2‐OE‐EHTs, which is suggestive of the systolic dysfunction observed clinically in DCM. Collectively, these results provide the first functional evidence that the TNNT2‐R151W mutation leads to pediatric DCM by causing sarcomere insufficiency and disturbances in Ca 2+ handling. Our patient‐specific iPSC‐EHT platform faithfully recapitulates key features of pediatric DCM and could offer a robust system for mechanistic studies and drug testing. Furthermore, phenotypic rescue upon overexpression of wild‐type TNNT2 suggests that this allele is amenable to a gene replacement approach aimed at restoring wild‐type function in TNNT2‐mutant cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Nagashima et al. (2026) studied this question. Overexpression of wild-type TNNT2 in patient-derived iPSCs restored contractile function and calcium handling in cardiomyocytes affected by the TNNT2-R151W mutation.
Synapse has enriched 10 related papers. Consider them for comparative context: